Yung-Chang Yen1, Charlene Lin2, Shih-Wei Lin3, Yung-Song Lin4,5, Shih-Feng Weng6,7. 1. Department of Ophthalmology, Chi Mei Medical Centre, Liou-Ying, Tainan City, Taiwan. 2. Department of Molecular and Cell Biology, University of California, Berkeley, California. 3. Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada. 4. Department of Otolaryngology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. 5. Department of Otolaryngology, Chi Mei Medical Center, Tainan, Taiwan. 6. Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan. 7. Department of Hospital and Health Care Administration, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan.
Abstract
BACKGROUND: The purpose of this study was to examine the effect of metformin on head and neck cancer in patients with diabetes. METHODS: We compared 66,600 patients, all with diabetes and all newly diagnosed with head and neck cancer in 2002. Half were being treated with metformin for diabetes (Met(+) ) and half were not (Met(-) : controls). All were matched for comorbidities (obesity, coronary artery disease, hyperlipidemia, and hypertension), sex, and age. The risk of head and neck cancer at the end of 2011 was determined. RESULTS: The incidence of head and neck cancer was 34% lower in the Met(+) cohort than in the Met(-) cohort (adjusted hazard ratio [HR] = 0.66; 95% confidence interval [CI] = 0.55-0.79). The risks for oropharyngeal cancer (adjusted HR = 0.66; 95% CI = 0.17-0.74) and nasopharyngeal carcinoma (NPC; adjusted HR = 0.50; 95% CI = 0.31-0.80) were significantly lower in the Met(+) cohort than in the Met(-) cohort. CONCLUSION: Metformin is associated with a lower risk of developing head and neck cancer in patients with diabetes.
BACKGROUND: The purpose of this study was to examine the effect of metformin on head and neck cancer in patients with diabetes. METHODS: We compared 66,600 patients, all with diabetes and all newly diagnosed with head and neck cancer in 2002. Half were being treated with metformin for diabetes (Met(+) ) and half were not (Met(-) : controls). All were matched for comorbidities (obesity, coronary artery disease, hyperlipidemia, and hypertension), sex, and age. The risk of head and neck cancer at the end of 2011 was determined. RESULTS: The incidence of head and neck cancer was 34% lower in the Met(+) cohort than in the Met(-) cohort (adjusted hazard ratio [HR] = 0.66; 95% confidence interval [CI] = 0.55-0.79). The risks for oropharyngeal cancer (adjusted HR = 0.66; 95% CI = 0.17-0.74) and nasopharyngeal carcinoma (NPC; adjusted HR = 0.50; 95% CI = 0.31-0.80) were significantly lower in the Met(+) cohort than in the Met(-) cohort. CONCLUSION:Metformin is associated with a lower risk of developing head and neck cancer in patients with diabetes.
Authors: Xingyu Wu; Huwate Yeerna; Yusuke Goto; Toshinori Ando; Victoria H Wu; Xuefeng Zhang; Zhiyong Wang; Panomwat Amornphimoltham; Anne N Murphy; Pablo Tamayo; Qianming Chen; Scott M Lippman; J Silvio Gutkind Journal: Cancer Res Date: 2019-07-10 Impact factor: 12.701
Authors: Dmitri Madera; Lynn Vitale-Cross; Daniel Martin; Abraham Schneider; Alfredo A Molinolo; Nitin Gangane; Thomas E Carey; Jonathan B McHugh; Christine M Komarck; Heather M Walline; William N William; Raja R Seethala; Robert L Ferris; J Silvio Gutkind Journal: Cancer Prev Res (Phila) Date: 2015-02-13
Authors: Sayuri Miyauchi; Sangwoo S Kim; John Pang; Kathryn A Gold; J Silvio Gutkind; Joseph A Califano; Loren K Mell; Ezra E W Cohen; Andrew B Sharabi Journal: Clin Cancer Res Date: 2019-02-27 Impact factor: 12.531
Authors: Daniel E Spratt; Beth M Beadle; Zachary S Zumsteg; Andrew Rivera; Heath D Skinner; Joseph R Osborne; Adam S Garden; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2015-11-11 Impact factor: 7.038
Authors: Alexander Gormley; Charlotte Richards; Francesca Spiga; Emily Gray; Joanna Hooper; Barry Main; Emma E Vincent; Rebecca Richmond; Julian Higgins; Mark Gormley Journal: BMJ Open Date: 2022-05-04 Impact factor: 3.006
Authors: Peter J Lancione; Bhavna Kumar; Songzhu Zhao; Edmund A Mroz; Guy Brock; James W Rocco; Ricardo L Carrau; Amit Agrawal; Nolan Seim; Stephen Y Kang; Enver Ozer; Matthew O Old Journal: Oral Oncol Date: 2020-05-07 Impact factor: 5.972
Authors: Ratna Veeramachaneni; Wangjie Yu; Jared M Newton; Jan O Kemnade; Heath D Skinner; Andrew G Sikora; Vlad C Sandulache Journal: J Immunother Cancer Date: 2021-07 Impact factor: 13.751